Sangamo Therapeutics (NASDAQ:SGMO) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Sangamo Therapeutics (NASDAQ:SGMO) in a report released on Wednesday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

A number of other research firms also recently issued reports on SGMO. HC Wainwright reissued a buy rating and set a $5.00 target price on shares of Sangamo Therapeutics in a research report on Wednesday, May 15th. Royal Bank of Canada reissued a sector perform rating and set a $2.00 target price on shares of Sangamo Therapeutics in a research report on Thursday, March 14th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of Hold and a consensus price target of $5.67.

Sangamo Therapeutics Price Performance

NASDAQ SGMO opened at $0.36 on Wednesday. Sangamo Therapeutics has a 12 month low of $0.29 and a 12 month high of $1.67. The company has a 50-day moving average of $0.54 and a 200-day moving average of $0.62. The company has a market cap of $74.35 million, a P/E ratio of -0.19 and a beta of 1.35.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.05). The business had revenue of $0.48 million for the quarter, compared to analyst estimates of $8.51 million. Sangamo Therapeutics had a negative return on equity of 182.55% and a negative net margin of 1,749.06%. During the same period last year, the company posted $0.12 EPS. As a group, equities research analysts anticipate that Sangamo Therapeutics will post -0.55 EPS for the current year.

Hedge Funds Weigh In On Sangamo Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of SGMO. Wasatch Advisors LP lifted its stake in Sangamo Therapeutics by 62.4% during the first quarter. Wasatch Advisors LP now owns 20,132,324 shares of the biopharmaceutical company’s stock worth $13,493,000 after purchasing an additional 7,734,400 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in Sangamo Therapeutics during the first quarter worth $331,000. Acadian Asset Management LLC lifted its stake in Sangamo Therapeutics by 4.0% during the first quarter. Acadian Asset Management LLC now owns 4,943,260 shares of the biopharmaceutical company’s stock worth $3,311,000 after purchasing an additional 192,385 shares during the last quarter. Assenagon Asset Management S.A. lifted its stake in Sangamo Therapeutics by 14.4% during the fourth quarter. Assenagon Asset Management S.A. now owns 1,033,322 shares of the biopharmaceutical company’s stock worth $561,000 after purchasing an additional 129,811 shares during the last quarter. Finally, SG Americas Securities LLC lifted its stake in Sangamo Therapeutics by 103.9% during the fourth quarter. SG Americas Securities LLC now owns 180,544 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 92,002 shares during the last quarter. Hedge funds and other institutional investors own 56.93% of the company’s stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.